-
Why Valeant, Not Endo, Could Still Win The War For Salix
Thursday, March 12, 2015 - 1:54pm | 344Read More...As reported on Wednesday, Endo International PLC (NASDAQ: ENDP) has made a takeover bid for Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), even though Valeant Pharmaceuticals Intl Inc (NYSE: VRX) already has an agreement to purchase the latter for roughly $10 billion. Sources familiar with the issue...
-
Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target
Wednesday, February 25, 2015 - 12:31pm | 177Read More...In a report published Wednesday, CRT Capital analyst Tim Chiang increased his price target on Buy-rated shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) to $220 from a previous $180 following Tuesday's conference call, which highlighted strong fundamentals and the strategic rationale...
-
CRT Raises Price Target On Valeant Pharmaceuticals, 'Well Positioned For Growth'
Friday, January 9, 2015 - 11:17am | 212Read More...CRT Capital raised its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from $170 to $180 and maintained a Buy rating. Analyst Tim Chiang noted that the company is “well positioned for growth in the specialty pharma industry, focused in the areas of dermatology and eye care in...
-
UPDATE: CRT Capital Upgrades Akorn
Friday, November 14, 2014 - 2:00pm | 257Read More...CRT Capital upgraded Akorn, Inc. (NASDAQ: AKRX) from Fair Value to Buy with a $46 price target. Analyst Tim Chiang believed “the recent sell off in AKRX shares post 3Q results creates a potential buying opportunity, based on our view that the Company will benefit from solid pricing trends...
